{
    "eid": "2-s2.0-84945281416",
    "title": "A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response",
    "cover-date": "2016-06-01",
    "subject-areas": [
        {
            "$": "Hepatology",
            "@code": "2721"
        },
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        },
        {
            "$": "Virology",
            "@code": "2406"
        }
    ],
    "keywords": [
        "entecavir",
        "HBsAg quantification",
        "peginterferon",
        "polymorphisms",
        "stopping rule"
    ],
    "authors": [
        "Pisit Tangkijvanich"
    ],
    "citedby-count": 33,
    "ref-count": 47,
    "ref-list": [
        "Hepatitis B virus infection",
        "Drug therapy: Hepatitis B virus infection",
        "Management of hepatitis B: Summary of a clinical research workshop",
        "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection",
        "Chronic hepatitis B: Update 2009",
        "Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B",
        "A randomized controlled trial of pegylated interferon-\u03b12a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B",
        "IL28B is associated with response to chronic hepatitis C interferon-\u03b1 and ribavirin therapy",
        "Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C",
        "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance",
        "Review article: Genetic factors that modify the outcome of viral hepatitis",
        "A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians",
        "Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B",
        "Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in Thai population",
        "IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6",
        "An algorithm for the grading of activity in chronic hepatitis C",
        "Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients",
        "Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a",
        "A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B \"e\" antigen-positive chronic hepatitis B",
        "Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-nave patients with chronic hepatitis B",
        "Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir",
        "Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers",
        "Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters",
        "HBsAg quantification: Useful for monitoring natural history and treatment outcome",
        "Decreasing Levels of HBsAg Predict HBsAg Seroclearance in Patients With Inactive Chronic Hepatitis B Virus Infection",
        "A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance",
        "Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients",
        "HBeAg-positive chronic hepatitis B: Why do I treat my patients with pegylated interferon?",
        "Predicting response to peginterferon \u03b1-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B",
        "A randomized trial of peginterferon \u03b1-2a with or without ribavirin for HBeAg-negative chronic hepatitis B",
        "On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients",
        "A new role for an old marker, HBsAg",
        "IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B",
        "Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir",
        "IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-\u03b1",
        "IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients",
        "Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B",
        "Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients",
        "HLA-DP and IL28B polymorphisms: Influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B",
        "Regulation of major histocompatibility complex class II gene expression, genetic variation and disease",
        "Optimal therapy of chronic hepatitis B: How do I treat my HBeAg-negative patients?",
        "Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype",
        "Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B",
        "Randomised study comparing 48 and 96 weeks peginterferon \u03b1-2a therapy in genotype D HBeAg-negative chronic hepatitis B",
        "Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes",
        "Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients",
        "Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "affilname": "Chulalongkorn University",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Merck, Sharp and Dohme Corp., and Grant for Chula Research Scholar",
        "Ratchadaphiseksomphot Endowment Fund",
        "Chulalongkorn University"
    ]
}